Dr. Laden co-founded TriStar Technology Ventures in 2009. Through his role at TriStar, he serves on the Board of Directors for VenX, Molecular Sensing, GOBA and Diagnovus. Prior to the founding of TriStar, Dr. Laden served as the Assistant Director in the Office of Technology Transfer and Enterprise Development at Vanderbilt University. That role involved leading various technology transfer functions for Vanderbilt, which included identifying, protecting, marketing and licensing promising new technologies to companies of all stages and sizes, as well as developing collaborative, sponsored R&D and material transfer relationships with industry. He also participated in the office’s venture investment and company formation activities. Since beginning as the Chancellor Fund in 2000, Vanderbilt invested a substantial amount of capital into 30 different Vanderbilt-related companies. Before moving into technology transfer, Dr. Laden was a postdoctoral researcher in the Department of Biochemistry at Vanderbilt, where his work focused on structure-function studies of the cytochromes P450. He holds a doctorate in Toxicology from the University of Kentucky, a master’s degree in Environmental and Industrial Health from the University of Michigan and an undergraduate degree in biology from Penn State University.
Current role